VANDA Pharmaceuticals - Investor Relations - IR Home

Investor Relations

Press Releases

Press Releases

Date Title and Summary Additional Formats
Toggle Summary European Medicines Agency Accepts Fanaptum® (iloperidone) Marketing Authorization Application for the Treatment of Schizophrenia in Adults
WASHINGTON , Dec. 22, 2015 /PRNewswire/ --  Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA) today announced that its Marketing Authorization Application (MAA) for oral Fanaptum ® tablets has been accepted for evaluation by the European Medicines Agency (EMA) for the treatment of schizophrenia in
View HTML
Toggle Summary Kenneth Bate Joins the Board of Directors of Vanda Pharmaceuticals
WASHINGTON , Dec. 18, 2015 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA), announced today that Kenneth Bate , an independent biotechnology industry consultant, has joined Vanda's Board of Directors. In connection with Mr. Bate's election, the Board has increased the number of
View HTML
Toggle Summary Vanda Pharmaceuticals appoints Gian Piero Reverberi as Acting Chief Commercial Officer
WASHINGTON , Dec. 17, 2015 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA) today announced that it has appointed Gian Piero Reverberi to the role of Senior Vice President, Acting Chief Commercial Officer and European General Manager.  Mr.
View HTML
Toggle Summary Vanda Pharmaceuticals Announces Participation at Upcoming Investor Conferences
WASHINGTON , Nov. 12, 2015 /PRNewswire/ --  Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA), a biopharmaceutical company focused on the development and commercialization of products for the treatment of central nervous system disorders, today announced that it will participate at the following
View HTML
Toggle Summary Vanda Pharmaceuticals to Participate in the Citi 2015 Global Healthcare 1x1 Conference
WASHINGTON , Nov. 4, 2015 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA), a biopharmaceutical company focused on the development and commercialization of products for the treatment of central nervous system disorders, today announced that Mihael H.
View HTML
Toggle Summary Vanda Pharmaceuticals Reports Third Quarter 2015 Financial Results
Vanda affirms its full year net product sales guidance of between $100 million and $115 million Conference call scheduled for 4:30 p.m. ET today WASHINGTON , Nov. 3, 2015 /PRNewswire/ --  Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA), today announced financial and operational results for the
View HTML
Toggle Summary Vanda Pharmaceuticals to Announce Third Quarter 2015 Financial Results on November 3, 2015
Conference Call and Webcast to Follow WASHINGTON , Oct. 15, 2015 /PRNewswire/ --  Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA) today announced it will release results for the third quarter of 2015 on Tuesday, November 3, 2015 , after the market closes.
View HTML
Toggle Summary Vanda Announces Listing of a New Fanapt® Patent in the FDA Orange Book
WASHINGTON , Oct. 14, 2015 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA) today announced that a Fanapt ® patent, number 9,157,121 ('121 patent), is now listed in the U.S. Food and Drug Administration publication Approved Drug Products With Therapeutic Equivalence Evaluations,
View HTML
Toggle Summary Vanda Announces Listing of a New Fanapt® Patent in the FDA Orange Book
WASHINGTON , Sept. 23, 2015 /PRNewswire/ --  Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA) today announced that a Fanapt ® patent, number 9,138,432 ('432 patent), is now listed in the U.S. Food and Drug Administration publication Approved Drug Products With Therapeutic Equivalence Evaluations,
View HTML
Toggle Summary Vanda Announces FDA Has Accepted for Review the Fanapt® Supplemental New Drug Application for Maintenance Treatment of Schizophrenia in Adults
WASHINGTON , Sept. 15, 2015 /PRNewswire/ --  Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA) today announced that the U.S. Food and Drug Administration ( FDA ) has accepted for review Vanda's filing of a supplemental New Drug Application (sNDA) for Fanapt ® seeking approval as a maintenance
View HTML
Toggle Summary Vanda Pharmaceuticals Announces the Appointment of General Counsel
WASHINGTON , Sept.14, 2015 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA) today announced that it has named Richard Gulino as Vanda's Senior Vice President, General Counsel and Secretary.  Mr. Gulino has over 20 years of strategic and legal experience representing life sciences
View HTML
Toggle Summary Vanda Announces Favorable Markman Ruling in Fanapt® Patent Infringement Litigation
WASHINGTON , Sept. 10, 2015 /PRNewswire/ --  Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA) today announced that a favorable Markman ruling has been issued by the United States District Court for the District of Delaware in the patent infringement lawsuit filed by Vanda against Roxane
View HTML
Toggle Summary Vanda Pharmaceuticals Announces the Appointment of European General Manager
WASHINGTON , Sept. 8, 2015 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA) today announced that it has named Gian Piero Reverberi as Vanda's Senior Vice President, European General Manager. Mr. Reverberi has more than 20 years of experience in the pharmaceutical industry, holding
View HTML
Toggle Summary Vanda Pharmaceuticals to Present at the Canaccord Genuity Annual Growth Conference
Presentation will be Webcast Live and Archived on Vanda's Website WASHINGTON , Aug. 10, 2015 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA), a biopharmaceutical company focused on the development and commercialization of products for the treatment of central nervous system
View HTML
Toggle Summary HETLIOZ® (tasimelteon) Phase III SET and RESET Trial Results Published in The Lancet
-- HETLIOZ®, when taken daily at a fixed time, promotes master body clock entrainment (synchronization) resulting in significant improvement across a number of sleep and wake parameters. -- Discontinuation of HETLIOZ® results in reversed clinical benefits reinforcing the importance of chronic
View HTML
Toggle Summary Vanda Announces Listing of Four New Fanapt® Patents in the FDA Orange Book
WASHINGTON , Aug. 3, 2015 /PRNewswire/ --  Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA) today announced that four new Fanapt ® patents are now listed in the U.S. Food and Drug Administration publication Approved Drug Products With Therapeutic Equivalence Evaluations, commonly known as the
View HTML
Toggle Summary Vanda Pharmaceuticals Reports Second Quarter 2015 Financial Results
- HETLIOZ® U.S. net product sales increased by 34% over the prior quarter to $10.0 million - Fanapt® U.S. net product sales increased by 20% over the prior quarter to $17.6 million - Vanda raises its full year net product sales guidance to between $100 million and $115 million Conference call
View HTML
Toggle Summary Vanda Pharmaceuticals to Announce Second Quarter 2015 Financial Results on July 29, 2015
Conference Call and Webcast to Follow WASHINGTON , July 9, 2015 /PRNewswire/ --  Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA) today announced it will release results for the second quarter of 2015 on Wednesday, July 29, 2015 , after the market closes.
View HTML
Toggle Summary HETLIOZ® Receives European Commission Approval for the Treatment of Non-24-Hour Sleep-Wake Disorder in the Totally Blind
- HETLIOZ®, a circadian regulator, is the first and only product to receive approval for Non-24 in the European Union WASHINGTON , July 7, 2015 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA) today announced that the European Commission (EC) approved HETLIOZ ® (tasimelteon) for
View HTML
Toggle Summary Vanda Announces Listing of a New HETLIOZ® Patent in the FDA Orange Book
WASHINGTON , July 2, 2015 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA) today announced that a HETLIOZ® patent, number 9,060,995 ('995 patent), is now listed in the U.S. Food and Drug Administration publication Approved Drug Products With Therapeutic Equivalence Evaluations,
View HTML
Toggle Summary Vanda Announces Positive Results from the Relapse Prevention Study in Patients with Schizophrenia (REPRIEVE) Demonstrating the Long-Term Maintenance Effects of Fanapt® (iloperidone)
WASHINGTON , June 23, 2015 /PRNewswire/ --  Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA), today presented positive results from the long-term maintenance REPRIEVE (Relapse prevention study in patients with schizophrenia) clinical study at the 2015 American Society of Clinical Pharmacology
View HTML
Toggle Summary Vanda Pharmaceuticals to Present at the JMP Securities Life Sciences Conference
Presentation will be Webcast Live and Archived on Vanda's Website WASHINGTON , June 19, 2015 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA), a biopharmaceutical company focused on the development and commercialization of products for the treatment of central nervous system
View HTML
Toggle Summary Vanda Pharmaceuticals to Present at the Jefferies 2015 Global Healthcare Conference
Presentation will be Webcast Live and Archived on Vanda's Website WASHINGTON , June 2, 2015 /PRNewswire/ --  Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA), a biopharmaceutical company focused on the development and commercialization of products for the treatment of central nervous system
View HTML
Toggle Summary Vanda Receives Innovation Award from the National Organization for Rare Disorders for Development of HETLIOZ®
WASHINGTON , May 26, 2015 /PRNewswire/ --  Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA) today announced that it has received the 2015 Industry Innovation Award from the National Organization of Rare Disorders (NORD) in recognition of Vanda's work in developing HETLIOZ ® (tasimelteon) for the
View HTML
Toggle Summary Vanda Pharmaceuticals to Present at the Bank of America Merrill Lynch 2015 Health Care Conference
Presentation will be Webcast Live and Archived on Vanda's Website WASHINGTON , May 11, 2015 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA), a biopharmaceutical company focused on the development and commercialization of products for the treatment of central nervous system
View HTML
Copyright © 2005-2020 Vanda Pharmaceuticals Inc. |